{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:59:43Z","timestamp":1785560383865,"version":"3.56.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bowel urgency (BU) is a disruptive ulcerative colitis (UC) symptom. Etrasimod, a sphingosine 1-phosphate (S1P)1,4,5 receptor modulator, improved BU in the ELEVATE UC clinical program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed associations between BU and efficacy endpoints, health-related quality of life (HRQoL), and biomarkers (Weeks 12 and 52) in patients receiving etrasimod in ELEVATE UC 52. A patient-reported numerical rating scale (NRS; 0-10; none to worst BU) assessed BU at baseline, Week 12, and Week 52. Binary BU outcomes were BU remission (NRS \u22641), clinically meaningful improvement in BU (NRS \u22653-point decrease), and complete BU remission (NRS\u2009=\u20090).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At Week 12, etrasimod-treated patients with BU remission were 4.0 times more likely to be in clinical remission (odds ratio [95% confidence interval (CI)]: 4.0 [2.3-7.1]; P\u2009&amp;lt;\u2009.0001) and 3.6 times more likely to show endoscopic improvement (3.6 [2.1-6.2]; P\u2009&amp;lt;\u2009.0001) versus patients without BU remission. Patients with BU remission also had significantly greater improvement in Inflammatory Bowel Disease Questionnaire: Total score (least squares mean difference [95% CI] 21.8 [13.5-30.1], P\u2009&amp;lt;\u2009.0001) and significantly lower fecal calprotectin and high-sensitivity C-reactive protein (mean [standard deviation] 744.5 [1,758.0] vs 2,314.2 [5,182.2] and 3.2 [5.8] vs 10.5 [24.9], respectively, both P\u2009&amp;lt;\u2009.0001). A similar association was seen for clinically meaningful improvement in BU and complete BU remission at Week 12 and all BU outcomes at Week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In etrasimod-treated patients, bowel urgency outcomes are positively associated with efficacy endpoints, HRQoL scores, and inflammatory biomarkers, and may be surrogate markers of disease activity and HRQoL improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov<\/jats:title>\n                    <jats:p>NCT03945188<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag072","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:46:03Z","timestamp":1784202363000},"source":"Crossref","is-referenced-by-count":0,"title":["Bowel urgency in ulcerative colitis is associated with clinical endpoints, health-related quality of life, and biomarkers: data from the etrasimod ELEVATE UC 52 trial"],"prefix":"10.1093","volume":"8","author":[{"given":"Marla C","family":"Dubinsky","sequence":"first","affiliation":[{"name":"Susan and Leonard Feinstein IBD Center, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica R","family":"Cohen","sequence":"additional","affiliation":[{"name":"Capital Digestive Care, Chevy Chase , Maryland, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"Irving","sequence":"additional","affiliation":[{"name":"IBD Unit, Guy\u2019s and St Thomas\u2019 Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Lazin","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Private Ltd , Chennai,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokul","family":"Pradeep","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Private Ltd , Chennai,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hur","sequence":"additional","affiliation":[{"name":"Pfizer Inc , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cognata","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7233-0933","authenticated-orcid":false,"given":"Karolina","family":"Wosik","sequence":"additional","affiliation":[{"name":"Pfizer Canada , Kirkland, QC,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary , Calgary, AB,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2026080100470284500_otag072-B1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2026080100470284500_otag072-B2","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026080100470284500_otag072-B3","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/MIB.0000000000000962","article-title":"Physical activity habits, limitations, and predictors in people with inflammatory bowel disease: a large cross-sectional online survey","volume":"22","author":"Tew","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026080100470284500_otag072-B4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cgh.2023.12.019","article-title":"Fecal urgency in ulcerative colitis: impact on quality of life and psychological well-being in active and inactive disease states","volume":"22","author":"Nigam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026080100470284500_otag072-B5","doi-asserted-by":"publisher","first-page":"813","DOI":"10.17219\/acem\/68986","article-title":"Stool patterns and symptoms of disordered anorectal function in patients with inflammatory bowel diseases","volume":"27","author":"Petryszyn","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"2026080100470284500_otag072-B6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00535-016-1241-x","article-title":"Impact of inflammatory bowel disease on Japanese patients\u2019 quality of life: results of a patient questionnaire survey","volume":"52","author":"Ueno","year":"2017","journal-title":"J Gastroenterol"},{"key":"2026080100470284500_otag072-B7","doi-asserted-by":"publisher","first-page":"otae047","DOI":"10.1093\/crocol\/otae047","article-title":"Burden of bowel urgency in patients with ulcerative colitis and crohn\u2019s disease: a real-world global study","volume":"6","author":"Atreya","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2026080100470284500_otag072-B8","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/ibd\/izae044","article-title":"Patient perspectives of bowel urgency and bowel urgency-related accidents in ulcerative colitis and Crohn\u2019s disease","volume":"30","author":"Jairath","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026080100470284500_otag072-B9","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.dld.2025.03.019","article-title":"Bowel urgency in ulcerative colitis assessed from patients\u2019 reports: results of a telemonitoring programme","volume":"57","author":"Carboni","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2026080100470284500_otag072-B10","first-page":"i1151-i","article-title":"The burden of urgency in ulcerative colitis: impact of disease duration and activity","volume":"19","author":"Singeap","year":"2025","journal-title":"Journal of Crohns & Colitis"},{"key":"2026080100470284500_otag072-B11","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s10620-023-08095-w","article-title":"Irritable bowel syndrome-like symptoms in quiescent inflammatory bowel disease: a practical approach to diagnosis and treatment of organic causes","volume":"68","author":"Lim","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026080100470284500_otag072-B12","doi-asserted-by":"publisher","first-page":"otac016","DOI":"10.1093\/crocol\/otac016","article-title":"Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis","volume":"4","author":"Dubinsky","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026080100470284500_otag072-B13","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026080100470284500_otag072-B14","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/jcag\/gwae059.094","article-title":"Association of bowel urgency with other disease activity measures in ulcerative colitis","volume":"8","author":"Gill","year":"2025","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026080100470284500_otag072-B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-022-00439-w","article-title":"Incorporating patient experience into drug development for ulcerative colitis: development of the urgency numeric rating scale, a patient-reported outcome measure to assess bowel urgency in adults","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026080100470284500_otag072-B16","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1007\/s11136-023-03494-y","article-title":"Validation of the bowel urgency numeric rating scale in patients with crohn\u2019s disease: results from a mixed methods study","volume":"32","author":"Dubinsky","year":"2023","journal-title":"Qual Life Res"},{"key":"2026080100470284500_otag072-B17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s41687-022-00522-2","article-title":"Psychometric evaluation of the urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis","volume":"6","author":"Dubinsky","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2026080100470284500_otag072-B18","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.14309\/01.ajg.0000954312.41350.0a","article-title":"Assessing bowel urgency in clinical practice: results from a healthcare professional survey","volume":"118","author":"Charabaty","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026080100470284500_otag072-B19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"2026080100470284500_otag072-B20","doi-asserted-by":"publisher","first-page":"e001838","DOI":"10.1136\/bmjgast-2025-001838","article-title":"Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme","volume":"12","author":"Chaparro","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"2026080100470284500_otag072-B21","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/ibd\/izae229","article-title":"Health-related quality of life outcomes with etrasimod treatment in patients with ulcerative colitis: a post hoc analysis of data from ELEVATE UC 52 and ELEVATE UC 12","volume":"31","author":"Armuzzi","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026080100470284500_otag072-B22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ibd.20301","article-title":"Quality of life of patients with ulcerative colitis: past, present, and future","volume":"14","author":"Irvine","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2026080100470284500_otag072-B23","doi-asserted-by":"publisher","first-page":"otae001","DOI":"10.1093\/crocol\/otae001","article-title":"Association of bowel urgency with quality-of-life measures in patients with moderately-to-severely active ulcerative colitis: results from phase 3 LUCENT-1 (induction) and LUCENT-2 (maintenance) studies","volume":"6","author":"Long","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2026080100470284500_otag072-B24","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/ecco-jcc\/jjab099","article-title":"Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis","volume":"15","author":"Ghosh","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026080100470284500_otag072-B25","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026080100470284500_otag072-B26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40271-019-00407-5","article-title":"A qualitative research for defining meaningful attributes for the treatment of inflammatory bowel disease from the patient perspective","volume":"13","author":"Louis","year":"2020","journal-title":"Patient"},{"key":"2026080100470284500_otag072-B27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ibd\/izad142","article-title":"The communicating needs and features of IBD experiences (CONFIDE) study: US and European patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis","volume":"30","author":"Travis","year":"2024","journal-title":"Inflamm Bowel Dis"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag072\/69028432\/otag072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag072\/69028432\/otag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag072\/69028432\/otag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:47:20Z","timestamp":1785559640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag072\/8735847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag072","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag072"}}